top of page

The contemporary research of Verthermia® in whole-body hyperthermia builds upon the century-old research of Wm. B. Coley who demonstrated that properly applied heat had therapeutic effects on tumors. During its two FDA Phase 1 clinical trials, Verthermia® demonstrated the effective application of its proprietary Hyperthermic Extracorporeal Applied Tumor Therapy (HEATT®) process, which exploits the cancer cell, the tumor, the tumor’s environment, and the metastasizing cancer cell’s travels via the blood stream. Since the 1980s Verthermia® has been studying and refining this technique which is delivered using the company’s patent-pending device, CoreHFC™. By raising the patient’s whole-body temperature to 42° Celsius, while keeping the blood flow moving throughout the body, cancer cells are damaged or destroyed. During the procedure, the patient's body functions are closely monitored to ensure that the body systems are functioning properly while exposed to heat. After the tumors are destroyed, the HEATT® process removes the toxic byproducts resulting from the procedure.

The Science of HEATT®


Why 42°C?

Through its decades of research, the Verthermia® team has discovered the effective and safe therapeutic temperature for whole body hyperthermia, as shown in its 2001 lung trial. Elevating the temperature to 41°C or higher results in the compromise of the cell structure of cancer cells. However, heating the temperature above 43°C results in destruction of normal cells. The positive effects of this therapeutic heating of the blood can be seen in the results of the two Phase 1 clinical trials conducted by Verthermia®.

bottom of page